Peptidomic analysis of CSF reveals new biomarker candidates for amyotrophic lateral sclerosis

ABSTRACT: Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease and novel biomarkers are needed. We applied mass-spectrometry-based peptidomic analysis in cerebrospinal fluid (CSF) samples of ALS and non-neurodegenerative control patients (Con) from a discovery (n=48) and validation (n=109) cohort for biomarker discovery. Systematic selection revealed a panel of eight novel peptide biomarker candidates for ALS (out of 33605) derived from seven proteins. In the validation cohort, NFL, MAP1B, MYL1, APOC1 peptides were up-regulated and peptides from CADM3, SCG1 and PENK down-regulated in ALS compared to Con. The peptides (except NFL) were not changed in other neurodegenerative diseases including Alzheimer´s disease, frontotemporal dementia and Parkinson´s disease. Combination o

SUBMITTER: Besnik Muqaku 

PROVIDER: S-SCDT-10_1038-S44321-025-00272-W | biostudies-other |

REPOSITORIES: biostudies-other